Her Fiancé Fired Her During the Shareholder Vote—Then the Prototype Responded Only to Her Voice

Part 3

Ben filed for an emergency injunction based on altered patent assignments and patient-data misuse.

Dr. Rosa Medina, the rehabilitation specialist who led our clinical program, gathered consent forms. None authorized facial recognition, law-enforcement profiling, or transfer of biometric models to a surveillance contractor.

I traced code commits while Jae reconstructed the hidden branch. Board minutes showed Miles repeatedly describing the Argus modules as “general analytics.” He scheduled technical presentations when I was treating my father or attending regulatory meetings.

Jae appeared loyal to him because he accepted a promotion and signed confidentiality agreements.

Then he showed us why.

He used the elevated access to create a forensic copy of every hidden commit. The drives contained timestamps, developer environments, and messages from an Argus engineer instructing Miles’s team to disguise facial models as fall-detection tools.

“I thought if I objected, they would delete it,” Jae said.

“You should have told me,” I replied.

“I was afraid you would confront them before I had proof.”

He was right about my impulse and wrong to remove my choice. Both facts mattered.

Graham’s role deepened.

He authorized broad patient-data access eighteen months earlier to meet growth targets. The policy allowed de-identified research use, but the safeguards were weak. Miles exploited the access to create identifiable profiles.

“I did not know the final purpose,” Graham said during a deposition.

“You knew the system collected more than patients consented to,” I replied.

“I believed we would revise the policy after financing.”

“That is a decision, not manipulation.”

He stopped calling himself deceived after that.

Miles released security footage showing me entering the server room at night and connecting a drive. The edited clip suggested I planted the hidden code before accusing the company.

The full footage showed I entered to restore a failed patient update months earlier. Ben obtained access logs proving the hidden branch existed before that date.

Still, the leak worked. News headlines called the dispute a founder feud. Patients received messages accusing me of threatening device support to regain control.

Then the network began failing.

At 8:14 on a Monday morning, Synapse devices in homes across three states displayed ACQUISITION AUTHORIZATION REQUIRED. Motors entered restricted mode. Patients could sit safely, but assisted walking and advanced functions would disable within one hour unless the Argus certificate was accepted.

Miles had built the acquisition into the operating system.

Victor called from his kitchen floor after his frame locked during a transfer.

“I am not hurt,” he said through clenched teeth. “But someone else will be.”

Graham stood in the operations center surrounded by alarms. “Can you stop it?”

“Yes.”

“What do you need?”

“My creator key, unrestricted network access, and written board authorization placing patient safety above the acquisition.”

Miles appeared by video from an unknown location. “Activating the creator key will trigger patent-control provisions and expose the company to seizure.”

I looked at the board members.

“They fired me because they said I was unsafe,” I said. “Now they must decide whether ownership matters more than people trapped inside their homes.”

The board authorized access.

I opened the system.

A countdown appeared across every screen.

Thirty-six minutes before advanced mobility functions disabled worldwide.

The technical investigation became a war over language. Miles called facial recognition an accessibility feature. Argus called patient profiles de-identified behavioral vectors. The board called covert collection a future product opportunity.

Rosa translated each phrase into consequences.

“A camera sees a patient fall,” she told investigators. “That can be used to call for help. The same camera sees how she walks, when she sleeps, who visits, and whether pain changes her expression. Without limits, safety becomes surveillance by another name.”

Jae reconstructed a demonstration Argus requested. The system identified Victor by gait through a wall of low-resolution footage even when his face was hidden. It could infer medication changes from movement and detect emotional distress from posture.

The capability impressed the engineers.

It frightened the people whose bodies trained it.

Miles attempted to buy Jae’s silence with a severance package and immigration support for a relative. Jae forwarded the offer to regulators. He also admitted he delayed telling me because he feared I would shut the system down before preserving evidence.

“I might have,” I said.

“That does not make the decision mine.”

He nodded. “I know.”

We rebuilt trust through tasks rather than declarations. Jae documented every access. Ben required two-person review of patent files. Rosa brought patient representatives into technical meetings, where engineers learned that a feature could be elegant and still unacceptable.

Graham attended one board interview and was asked whether he planned to restore me after the acquisition.

“Yes,” he said.

“Did Ms. Lin know that?”

“No.”

“Then how was it a plan rather than a fantasy that excused your conduct?”

He had no answer.

The edited footage accusing me of sabotage spread through investor channels. A television host called me a disgruntled founder who could not tolerate professional management. Patients began receiving threatening messages for supporting me.

I considered releasing every internal document at once.

Ben stopped me. “Evidence has to survive court, not only win the internet.”

So we preserved, authenticated, and disclosed through regulators. Restraint felt like silence until I learned the difference between waiting for truth and hiding it.

The civil case over the patent assignments lasted longer than the criminal investigation. Handwriting experts confirmed my signatures, while document metadata showed page substitution after Ben reviewed the drafts. Emails placed Miles’s assistant at the print room and Graham on a call where the change was described as “cleaning founder contingencies.”

Graham claimed he did not understand that phrase meant permanent transfer. He also admitted he did not ask because the financing deadline mattered more.

The court restored my ownership and invalidated the altered assignment. I licensed the technology to support existing patients rather than withdrawing it from the company in retaliation.

Some supporters wanted me to bankrupt Synapse Motion. The veteran objected.

“We need the devices,” he said. “Justice that strands patients is still designed around founders.”

His correction shaped the settlement. The company survived as a service entity under the patient trust, while Lin Mobility developed future systems.

At the first cooperative board meeting, patients voted against a feature I personally favored. I accepted the vote.

Shared control was not meaningful only when others agreed with me.

The patient advisory meetings were harder than any investor presentation. People described devices freezing in grocery aisles, privacy settings that changed after updates, and customer-support scripts that treated disabled users like unreliable narrators of their own equipment.

I had designed the core interface, but I had not designed every policy built around it. That did not allow me to distance myself from the system carrying my name.

The veteran asked why the emergency mode sent data to company servers before notifying a chosen caregiver.

“Engineers wanted diagnostic information,” I said.

“Patients wanted help.”

The cooperative reversed the order.

Another patient asked why the device used the phrase noncompliant user when someone rejected an update. I deleted the phrase from the standard while she watched.

Graham attended as a nonvoting observer. Once, he began answering a question directed at me, then stopped himself.

“Sorry,” he said. “Avery should answer.”

“No,” I told him. “The patient should.”

We waited while the woman explained what safety meant from her chair rather than from our conference table.

The lesson was uncomfortable precisely because none of us could convert it into a heroic founder story.

Before the cooperative launch, we invited users to test failure scenarios rather than polished demonstrations. One woman asked what happened if the company disappeared overnight. Another asked whether a caregiver could override her refusal simply by claiming an emergency.

Our old answers depended on corporate judgment. The new system required documented patient choices, limited emergency access, and an audit visible to the person using the device.

Graham attended the session without speaking until The veteran asked him directly why the original company had prioritized investor control.

“Because I believed capital kept the technology alive,” he said.

“And patients?”

“I treated them as beneficiaries of survival rather than owners of the risk.”

Victor nodded. “That is the correct answer. It is not a comfortable one.”

Neither man looked at me for approval. The exchange belonged to the people whose bodies the software moved.

When the first revised interface failed during testing, no executive hid the error before the demonstration. We documented it, corrected it, and invited the same users back.

Trust grew less from perfection than from losing the power to conceal imperfection.

The revised device log recorded every override in language patients could understand, not only codes engineers could defend.